Publication at First Faculty of Medicine, Faculty of Medicine in Hradec Králové |
2014
Abstract
The long-acting injection formulation of aripiprazole (ALAI) is intended for the maintenance treatment of schizophrenia in adult patients who have been stalilized on oral aripiprazole. The recommended dosing schedule is one month.
Two large registration trials confirmed efficacy of ALAI in the prevention of schizophrenia relapse. ALAI was superior to placebo and demonstrated non-inferiority to oral formulation of aripiprazole in the delay of psychotic exacerbation or impending relapse and in the reduction of relapse rates.
ALAI was well tolerated; its side effect profile corresponded to that observed in tablet formulation. ALAI is the first long-acting antipsychotic with partial agonistic action at D2 receptors.